Related references
Note: Only part of the references are listed.An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center
Audrea H. Szabatura et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2015)
Aprepitant: drug-drug interactions in perspective
M. S. Aapro et al.
ANNALS OF ONCOLOGY (2010)
Effectiveness of Exogenous Albumin Administration for the Prevention of Ifosfamide-Induced Encephalopathy
Jacob K. Kettle et al.
PHARMACOTHERAPY (2010)
Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity
Ashley Richards et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2010)
Letter to the editor
G. Lombardi et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2009)
Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant
Joshua E Howell et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2008)
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas
Metin Tascilar et al.
ONCOLOGIST (2007)
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature
J Pelgrims et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
